Immunotherapy for Grave's orbitopathy: Easy enthusiasm, but let's keep trying

Journal of Endocrinological Investigation

Volumn 29, Issue 11, 2006, Pages 1012-1016

  Bartalena, Luigi ^a   Tanda, M L ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

B cells; CTLA 4; Cytokine antagonists; Etanercept; Grave's orbitopathy; Rituximab; T cells

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ATLIZUMAB; CD3 ANTIBODY; ETANERCEPT; GLUCOCORTICOID; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN; INFLIXIMAB; INSULIN; INTERLEUKIN 10; INTERLEUKIN 8; LYMPHOTOXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SOMATOSTATIN DERIVATIVE; THIAMAZOLE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; CANCER ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADIPOCYTE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DECOMPRESSION SURGERY; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL FACTOR; FIBROBLAST; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MONONUCLEOSIS; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN TARGETING; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ECONOMICS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33846952543     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349216     Document Type: Article

References (34)

1. Bartalena L, Marcocci C, Pinchera A. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168-99.
2. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003, 24: 802-35.
3. Bartalena L, Wiersinga WM, Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004, 27: 295-301.
4. Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 2005, 28: 469-78.
5. Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 2004, 27: 259-64.
6. Tanda ML, Bartalena L. Currently available somatostatin analogs are not good for Graves' orbitopathy. J Endocrinol Invest 2006, 29: 389-90.
7. Garrity JA, Bahn RS. Pathogenesis of Graves'ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006, 142: 147-53.
8. Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 237-45.
9. Starkey K, Heufelder A, Baker G, et al. Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003, 88: 55-9.
10. Mimura LY, Villares SMF, Monteiro MLR, Guazzelli IC, Bloise W. Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/coonnective tissues is increased during the active stage of Graves' ophthalmopathy. Thyroid 2003, 13: 845-50.
11. Feldon SE, Park DJJ, O'Loughlin CW, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2005, 46: 3913-21.
12. Drexhage HA. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves' disease? Endocrinology 2005, 147: 9-12.
13. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295: 2275-85.
14. Gudbrandsdottir S, Larsen R, Sorensen LK, et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004, 22: 118-24.
15. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005, 19: 1286-9.
16. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6: 859-66.
17. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20. What do B-cells do? Clin Immunol 2005, 117: 207-13.
18. Traullè C, Coiffier BB. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol 2005, 1: 297-306.
19. Eisenberg R. Update on rituximab. Ann Rheum Dis 2005, 64: 55-7.
20. El Fassi D, Nielsen CH, Hasselbach HC, Hegedus L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006, 154: 623-32.
21. Hasselbach HC. B cell depletion with rituximab - a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett 2003, 88: 85-6.
22. El Fassi D, Nielsen CH, Hasselbach HC, Hegedus L. Successful B lymphocyte depletion with rituximab in a patient with recurrent Graves' disease and severe ophthalmopathy. Thyroid 2005, 15: S28.
23. Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154: 511-7.
24. Wiersinga WM, Prummel MF. Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002, 13: 280-7.
25. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352: 259-608.
26. O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci 2006, 11: 1620-35.
27. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349: 1907-15.
28. Alegre M-L, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des 2006, 12: 149-60.
29. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005, 5: 39-51.
30. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005, 10: 79-93.
31. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354: 1601-5.
32. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996, 81: 449-52.
33. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63: 1062-8.
34. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50: 1761-9.